Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von Willebrand disease, and factor VII deficiency

ILAR Journal

Volumn 50, Issue 2, 2009, Pages 144-167

  Nichols, Timothy C ^a   Dillow, Aaron M ^a   Franck, Helen W G ^a   Merricks, Elizabeth P ^a   Raymer, Robin A ^a   Bellinger, Dwight A ^a   Arruda, Valder R ^a,b   High, Katherine A ^a,b,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Coagulation assays; Dog model; Factor IX; Factor VII; Factor VIII; Hemophilia; Von Willebrand disease; Von Willebrand factor

Indexed keywords

BACTERIA (MICROORGANISMS); CANIS FAMILIARIS; MIRIDAE; PRIMATES; RODENTIA;

PROTEIN; VON WILLEBRAND FACTOR;

ANIMAL; BLOOD CLOTTING; BLOOD CLOTTING FACTOR 7 DEFICIENCY; DISEASE MODEL; DOG; GENE THERAPY; GENE VECTOR; GENETICS; HEMOPHILIA A; HEMOPHILIA B; LIVER TRANSPLANTATION; METABOLISM; METHODOLOGY; PHYSIOLOGY; REVIEW; VON WILLEBRAND DISEASE;

ANIMALS; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; DOGS; FACTOR VII DEFICIENCY; GENE THERAPY; GENETIC VECTORS; HEMOPHILIA A; HEMOPHILIA B; LIVER TRANSPLANTATION; PROTEINS; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 66149110999     PISSN: 10842020     EISSN: None     Source Type: Journal    
DOI: 10.1093/ilar.50.2.144     Document Type: Review

References (265)

1. Aledort LM, DiMichele DM. 1998. Inhibitors occur more frequently in Africo-Americans and Latino hæmophiliacs. Hæmophilia 80:779-783.
2. Aljamali MN, Margaritis P, Schlachterman A, Tai SJ, Roy E, Bunte R, Camire RM, High KA. 2008. Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality. J Clin Invest 118:1825-1834.
3. Andersson LO, Forsman N, Huang K, Larsen K, Lundin A, Pavlu B, Sandberg H, Sewerin K, Smart J. 1986. Isolation and characterization of human factor VIII: Molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma. Proc Natl Acad Sci U S A 83:2979-2783.
4. Antonarakis SE, Rossiter JP, Young M, Horst J, Moerloose P de, Sommer SS, Ketterling RP, Kazazian HH Jr, Negrier C, Vinciguerra C, Gitschier J, Goossens M, Girodon E, Ghanem N, Plassa F, Lavergne JM, Vidaud M, Costa JM, Laurian Y, Lin S-W, Lin S-R, Shen M-C, Lillicrap D, Taylor SAM, Windsor S, Valleix SV, Nafa K, Sultan Y, Delpech M, Vnencak-Jones C, Phillips JA III, Ljung RCR, Koumbarelis E, Gialeraki A, Mandalaki T, Jenkins PV, Collins PW, Pasi KJ, Goodeve A, Peake I, Preston FE, Schwartz M, Scheibel E, Ingerslev J, Cooper DN, Millar DS, Kakkar VV, Giannelli F, Naylor JA, Tizzano EF, Baiget M, Domenech M, Altisent C, Tusell J, Beneyto M, Lorenzo JI, Gaucher C, Mazurier C, Peerlinck GMK, Matthijs K, Cassiman JJ, Vermylen J, Mori PG, Acquila M, Caprino D, Inaba H. 1995. Factor VIII gene inversions in severe hemophilia A: Results of an international consortium study. Blood 86:2206-2212.
5. Arruda VR. 2006. Toward gene therapy for hemophilia A with novel adenoviral vectors: Successes and limitations in canine models. J Thromb Hæmost 4:1215-1217.
6. Arruda VR, Fields PA, Milner R, Wainwright L, De Miguel P, Donavan PJ, Herzog RW, Nichols TC, Biegel JA, Razavi M, Dake M, Huff D, Flake AW, Couto L, Kay M, High KA. 2001. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vectors in males. Mol Ther 4:586-592.
7. Arruda VR, Scallan C, Jiang H, Couto L, Herzog RW, Nichols TC, Pierce G, High KA. 2004a. Comparison of the efficacy on gene transfer by AAV vectors delivered by distinct routes of administration to the liver of hemophilia B dogs. Mol Ther 9 (abstr suppl):S103.
8. Arruda VR, Schuettrumpf J, Herzog RW, Nichols TC, Robinson N, Lotfi Y, Mingozzi F, Xiao W, Couto LB, High KA. 2004b. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood 103:85-92.
9. Arruda VR, Stedman HH, Schuettrumpf J, Jiang H, Pierce G, Nichols TC, High KA. 2004c. A novel method of regional intravenous delivery of AAV vector to skeletal muscle results in correction of canine hemophilia B phenotype. Blood 104:abstract 3179.
10. Arruda VR, Stedman HH, Nichols TC, Haskins ME, Nicholson M, Herzog RW, Couto LB, High KA. 2005. Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood 105:3458-3464.
11. Astermark J. 2006. Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors. Hæmophilia 12 Suppl 6:8-13; discussion 13-14.
12. Axelrod JH, Read MS, Brinkhous KM, Verma IM. 1990. Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs. Proc Natl Acad Sci U S A 87:5173-5177.
13. Balagué C, Zhou JM, Dai YF, Alemany R, Josephs SF, Andreason G, Hariharan M, Sethi E, Prokopenko E, Jan HY, Lou YC, Hubert-Leslie D, Ruiz L, Zhang WW. 2000. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. Blood 95:820-828.
14. Bauer TR Jr, Adler, RL, Hickstein DD. 2009. Potential large animal models for gene therapy of human genetic diseases of immune and blood cell systems. ILAR J 50:168-186.
15. Bellinger DA, Nichols TC, Read MS, Reddick RL, Lamb MA, Brinkhous KM, Evatt BL, Griggs TR. 1987. Prevention of occlusive coronary artery thrombosis by a murine monoclonal antibody to porcine von Willebrand factor. Proc Natl Acad Sci U S A 84:8100-8104.
16. Biggs R, Douglas AS, Macfarlane RG, Dacie JV, Pitney WR, Merskey. 1952. Christmas disease: A condition previously mistaken for hæmophilia. Br Med J 2:1378-1382.
17. Bowie EJW, Solberg LA, Fass DN, Johnson CM, Knutson GJ, Stewart ML, Zoecklein LJ. 1986. Transplantation of normal bone marrow into a pig with severe von Willebrand's disease. J Clin Invest 78:26-30.
18. Brinkhous KM, Graham JB. 1950. Hemophilia in the female dog. Science 111:723.
19. Brinkhous KM, Morrison FCJ, Muhrer ME. 1952. Comparative study of clotting defects in human, canine, and porcine hemophilia. Fed Proc 11:409a.
20. Brinkhous KM, Penick GD, Langdell RD, Wagner RH, Graham JB. 1956. Physiologic basis of transfusion therapy in hemophilia. Arch Pathol 61:6-10.
21. Brinkhous KM, Shanbrom E, Roberts HR, Webster WP, Fekete L, Wagner RH. 1968. A new high-potency glycine-precipitated anti-hemophilic factor (AHF) concentrate: Treatment of classical hemophilia and hemophilia with inhibitors. JAMA 205:613-617.
22. Brinkhous KM, Sandberg H, Garris JB, Mattsson C, Palm M, Griggs TR, Read MS. 1985. Purified human factor VIII procoagulant protein: Comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci U S A 82:8752-8756.
23. Brinkhous KM, Hedner U, Garris JB, Diness V, Read MS. 1989a. Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease. Proc Natl Acad Sci U S A 86:1382-1386.
24. Brinkhous KM, Reddick RL, Griggs TR. 1989b. Arterial thrombosis, atherosclerosis, and the factor VIII/von Willebrand factor complex. In: Zimmerman TS, Ruggeri ZM, eds. Coagulation and Bleeding Disorders: The Role of Factor VIII and von Willebrand Factor. New York and Basel: Marcel Dekker. p 283-303.
25. Brinkhous KM, Sigman JL, Read MS, Stewart PF, McCarthy KP, Timony GA, Leppanen SD, Rup BJ, Keith JC Jr, Schaub RG. 1996. Recombinant human factor IX: Replacement therapy, prophylaxis, pharmacokinetics, and immunogenicity in canine hemophilia B. Blood 88:2603-2610.
26. Brinkhous KM, Sandberg H, Widlund L, Read MS, Nichols TC, Sigman J, Oswaldsson U, Schaub RG, Mikaelsson M. 2002. Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII. Semin Thromb Hemost 28:269-272.
27. Brooks MB, Gu W, Ray K. 1997. Complete deletion of factor IX gene and inhibition of factor IX activity in a labrador retriever with hemophilia B. JAVMA 211:1418-1421.
28. Brooks MB, Gu W, Barnas JL, Ray J, Ray K. 2003. A Line 1 insertion in the factor IX gene segregates with mild hemophilia B in dogs. Mamm Genome 14:788-795.
29. Brown BD, Shi CX, Powell S, Hurlbut D, Graham FL, Lillicrap D. 2004. Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A. Blood 103:804-810.
30. Brown BD, Venneri MA, Zingale A, Sergi Sergi L, Naldini L. 2006. Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med 12:585-591.
31. Brown BD, Cantore A, Annoni A, Sergi LS, Lombardo A, Della Valle P, D'Angelo A, Naldini L. 2007. A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood 110:4144-4152.
32. Brunetti-Pierri N, Nichols TC, McCorquodale S, Merricks E, Palmer DJ, Beaudet AL, Ng P. 2005. Sustained phenotypic correction of canine hemophilia B following systemic administration of helper dependent adenoviral vector. Hum Gene Ther 16:811-820.
33. Burton M, Nakai H, Colosi P, Cunningham J, Mitchell R, Couto L. 1999. Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein. Proc Natl Acad Sci U S A 96:12725-12730.
34. Callan MB, Aljamali MN, Margaritis P, Griot-Wenk ME, Pollak ES, Werner P, Giger U, High KA. 2006. A novel missense mutation responsible for factor VII deficiency in research Beagle colonies. J Thromb Hæmost 4:2616-2622.
35. Cameron C, Notley C, Hoyle S, McGlynn L, Hough C, Kamisue S, Giles A, Lillicrap DA. 1998. The canine factor VIII cDNA and 5′ flanking sequence. Thromb Hæmost 79:317-322.
36. Casal M, Haskins M. 2006. Large animal models and gene therapy. Eur J Hum Genet 14:266-272.
37. Castillo R, Mateagudo J, Escolar G, Ordinas A, Magallon M, Villar JM. 1991. Hemostatic effect of normal platelet transfusion in severe von Willebrand disease patients. Blood 77:1901-1905.
38. Chang PL, Shen N, Westcott AJ. 1993. Delivery of recombinant gene products with microencapsulated cells in vivo. Hum Gene Ther 4:433-440.
39. Chang JY, Monroe DM, Stafford DW, Brinkhous KM, Roberts HR. 1997. Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B. J Clin Invest 100:886-892.
40. Chao H, Samulski R, Bellinger D, Monahan P, Nichols T, Walsh C. 1999. Persistent expression of canine factor IX in hemophilia B canines. Gene Ther 6:1695-1704.
41. Chao H, Mao L, Bruce AT, Walsh CE. 2000. Sustained expression of human factor VIII in mice using a parvovirus-based vector. Blood 95:1594-1599.
42. Chen L, Zhu F, Li J, Lu H, Jiang H, Sarkar R, Arruda VR, Wang J, Zhao J, Pierce GF, Ding Q, Wang X, Wang H, Pipe SW, Liu XQ, Xiao X, Camire RM, Xiao W. 2007. The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene. Mol Ther 15:1856-1862.
43. Chen L, Lu H, Wang J, Sarkar R, Yang X, Wang H, High KA, Xiao W. 2009. Enhanced factor VIII heavy chain for gene therapy of hemophilia A. Mol Ther, Epub PMID 19127250.
44. Cheung WF, van den Born J, Kuhn K, Kjellen L, Hudson BG, Stafford DW. 1996. Identification of the endothelial cell binding site for factor IX. Proc Natl Acad Sci U S A 93:11068-11073.
45. Chuah MK, Schiedner G, Thorrez L, Brown B, Johnston M, Gillijns V, Hertel S, Van Rooijen N, Lillicrap D, Collen D, VandenDriessche T, Kochanek S. 2003. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood 101:1734-1743.
46. Chuah MK, Collen D, Vandendriessche T. 2004. Preclinical and clinical gene therapy for hæmophilia. Hæmophilia 10 Suppl 4:119-125.
47. Connelly S, Kaleko M. 1997. Gene therapy for hemophilia A. Thromb Hæmost 78:31-36.
48. Cramer EM, Caen JP, Drouet L, Breton-Gorius J. 1986. Absence of tubular structures and immunolabeling for von Willebrand factor in the platelet α-granules from porcine von Willebrand disease. Blood 86:774-778.
49. Cristiano RJ, Smith LC, Kay MA, Brinkley BR, Woo SLC. 1993. Hepatic gene therapy: Efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. Proc Natl Acad Sci U S A 90:11548-11552.
50. De Meyer SF, Vanhoorelbeke K, Chuah MK, Pareyn I, Gillijns V, Hebbel RP, Collen D, Deckmyn H, VandenDriessche T. 2006. Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor. Blood 107:4728-4736.
51. De Meyer SF, Pareyn I, Baert J, Deckmyn H, Vanhoorelbeke K. 2007. False positive results in chimeraplasty for von Willebrand Disease. Thromb Res 119:93-104.
52. Denis CV, Kwack K, Saffaripour S, Maganti S, André P, Schaub RG, Wagner DD. 2001. Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models. Blood 97:465-472.
53. Denis CV, Andre P, Saffaripour S, Wagner DD. 2001. Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factor-deficient mice. Proc Natl Acad Sci U S A 98:4072-4077.
54. DiMichele D. 2007. Immune tolerance therapy for factor VIII inhibitors: Moving from empiricism to an evidence-based approach. J Thromb Hæmost 5 Suppl 1:143-150.
55. Donsante A, Vogler C, Muzyczka N, Crawford JM, Barker J, Flotte T, Campbell-Thompson M, Daly T, Sands MS. 2001. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther 8:1343-1346.
56. Donsante A, Miller DG, Li Y, Vogler C, Brunt EM, Russell DW, Sands MS. 2007. AAV vector integration sites in mouse hepatocellular carcinoma. Science 317:477.
57. Ehrhardt A, Kay MA. 2002. A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood 99:3923-3930.
58. Ehrhardt A, Xu H, Dillow AM, Bellinger DA, Nichols TC, Kay MA. 2003. A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia. Blood 102:2403-2411.
59. Ehrhardt A, Xu H, Dillow AM, Yant SR, Nichols TC, Kay MA. 2006. Transposition from a gene-deleted adenoviral vector results in phenotypic correction in a canine model of hemophilia B. Mol Ther 13:S5.
60. Eisensmith RC, Woo SL. 1997. Viral vector-mediated gene therapy for hemophilia B. [Review]. Thromb Hæmost 78:24-30.
61. Evans JP, Brinkhous KM, Brayer GD, Reisner HM, High KA. 1989a. Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci U S A 86:10095-10099.
62. Evans JP, Watzke HH, Ware JL, Stafford DW, High KA. 1989b. Molecular cloning of a cDNA encoding canine factor IX. Blood 74:207-212.
63. Fang B, Eisensmith RC, Wang H, Kay MA, Cross RE, Landen CN, Gordon G, Bellinger DA, Read MS, Hu PC, Brinkhous KM, Woo SLC. 1995. Gene therapy for hemophilia B: Host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 6:1039-1044.
64. Fang B, Wang H, Gordon G, Bellinger DA, Read MS, Brinkhous KM, Woo SLC, Eisensmith RC. 1996. Lack of persistence of E1 recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Gene Ther 3:217-222.
65. Fang X, Zhang WW, Sobol RE, Gomperts E, Thompson AR, Wong WY, Kohn D, Rogers R, Fischer T, Nichols T, Murthy KK, Cobb EK, Fahs S, Montgomery RR, White G. 2000. Studies in nonhuman primate and hemophilic dog models of a "gutless" adenovirus vector for treatment of hemophilia A. Blood 96:428a.
66. Federici AB, Castaman G, Thompson A, Berntorp E. 2006. Von Willebrand's disease: Clinical management. Hæmophilia 12 Suppl 3:152-158.
67. Fewell JG, Bruce D, Florack V, Wilson E, Anscombe I, Nolan E, Read MS, Bellinger DA, Fischer TH, Nichols TC, Smith LC. 2000. Expression of Factor IX in mice and hemophilic B dogs following intramuscular injection of PINC™-formulated plasmid with electroporation. Blood 96:803a.
68. Fewell JG, MacLaughlin F, Mehta V, Gondo M, Nicol F, Wilson E, Smith LC. 2001. Gene therapy for the treatment of hemophilia B using PINC-formulated plasmid delivered to muscle with electroporation. Mol Ther 3:574-583.
69. Finn JD, Sabatino DE, Ozelo MC, Zhou S, Lillicrap D, Kazazian HH, Nichols TC, Arruda VR. 2008. Induction of immune tolerance to canine FVIII in hemophilia A dogs with inhibitors using AAV-mediated expression of canine FVIII. Blood 112:Abstract 243.
70. Follenzi A, Battaglia M, Lombardo A, Annoni A, Roncarolo MG, Naldini L. 2004. Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood 103:3700-3709.
71. Follenzi A, Benten D, Novikoff P, Faulkner L, Raut S, Gupta S. 2008. Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice. J Clin Invest 118:935-945.
72. Gailani D, Renne T. 2007. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscl Throm Vas 27:2507-2513.
73. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. 2002. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 99:11854-11859.
74. Gewirtz J, Thornton MA, Rauova L, Poncz M. 2008. Platelet-delivered factor VIII provides limited resistance to anti-factor VIII inhibitors. J Thromb Hæmost 6:1160-1166.
75. Ghosh S, Ezban M, Persson E, Pendurthi U, Hedner U, Rao LV. 2007. Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface. J Thromb Hæmost 5:336-346.
76. Giles AR, Tinlin S, Hoogendoorn H, Greenwood P, Greenwood R. 1984. Development of factor VIII:C antibodies in dogs with hemophilia A (factor VIII:C deficiency). Blood 63:451-456.
77. Gillis S, Furie BC, Furie B, Patel H, Huberty MC, Switzer M, Foster WB, Scoble HA, Bond MD. 1997. gamma-Carboxyglutamic acids 36 and 40 do not contribute to human factor IX function. Protein Sci 6:185-196.
78. Goldsmith JC, Chung KS, Roberts HR. 1978. A simple assay for human factor IX: Use of canine hemophilia B plasma as substrate. Thromb Res 12:497-502.
79. Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Hashemi Soteh M, Baronciani L, Hallden C, Guilliatt A, Lester W, Peake I. 2007. Phenotype and genotype of a cohort of families historically diagnosed with Type 1 von Willebrand disease in the European study: Molecular and clinical markers for the diagnosis and management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 109:112-121 (erratum in: Blood 111:3299-3300).
80. Goudemand J, Rothschild C, Demiguel V, Vinciguerrat C, Lambert T, Chambost H, Borel-Derlon A, Claeyssens S, Laurian Y, Calvez T. 2006. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 107:46-51.
81. Graham JB, Buckwalter JA, Hartley LJ, Brinkhous KM. 1949. Canine hemophilia: Observations on the course, the clotting anomaly, and the effects of blood transfusion. J Exp Med 90:97-111.
82. Gralnick HR, Rick ME, McKeown LP, Williams SB, Parker RI, Maisonneuve P, Jenneau C, Sultan Y. 1986. Platelet von Willebrand factor: An important determinant of the bleeding time in type I von Willebrand's disease. Blood 68:58-61.
83. Greelish JP, Su LT, Lankford EB, Burkman JM, Chen H, Konig SK, Mercier IM, Desjardins PR, Mitchell MA, Zheng XG, Leferovich J, Gao GP, Balice-Gordon RJ, Wilson JM, Stedman HH. 1999. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat Med 5:439-443.
84. Greengard JS, Bodner M, McCormack J, Edwards WR, Sensintaffar JL, Sheridan PL, Phuong T, Mittelstaedt D, Brumm D, Nichols TC, Read M, Brinkhous KM, Jolly DJ, Chang SMW. 1997. Sustained expression of human factor VIII from peripheral retroviral gene delivery in rabbits and dogs. Blood 90:240a.
85. Gu W, Brooks M, Catalfamo J, Ray J, Ray K. 1999. Two distinct mutations cause severe hemophilia B in two unrelated canine pedigrees. Thromb Hæmost 82:1270-1275.
86. Haberichter SL, Fahs SA, Montgomery RR. 2000. von Willebrand factor storage and multimerization: 2 independent intracellular processes. Blood 96:1808-1815.
87. Haberichter SL, Merricks EP, Fahs SA, Christopherson PA, Nichols TC, Montgomery RR. 2005. Re-establishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells. Blood 105:145-152.
88. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A. 2003. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348:255-256.
89. Han Z, Zhong L, Maina N, Hu Z, Li X, Chouthai NS, Bischof D, Weigel-Van Aken KA, Slayton WB, Yoder MC, Srivastava A. 2008. Stable integration of recombinant adeno-associated virus vector genomes after transduction of murine hematopoietic stem cells. Hum Gene Ther 19:267-278.
90. Harding TC, Koprivnikar KE, Tu GH, Zayek N, Lew S, Subramanian A, Sivakumaran A, Frey D, Ho K, VanRoey MJ, Nichols TC, Bellinger DA, Yendluri S, Waugh J, McArthur J, Veres G, Donahue BA. 2004. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B. Gene Ther 11:204-213.
91. Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML. 1997. Construction of adenovirus vectors through CRE-lox recombination. J Virol 71:1842-1849.
92. Hasbrouck NC, High KA. 2008. AAV-mediated gene transfer for the treatment of hemophilia B: Problems and prospects. Gene Ther 15:870-875.
93. Haskins M. 2009. Gene therapy for lysosomal storage diseases (LSDs) in large animal models. ILAR J 50:112-121.
94. Hedner U. 2003. Recombinant factor VIIa (NovoSeven) as a hemostatic agent. Dis Mon 49:39-48.
95. Hedner U. 2004. Dosing with recombinant factor VIIa based on current evidence. Semin Hematol 41:35-39.
96. Heimark RL, Schwartz SM. 1983. Binding of coagulation factors IX and X to the endothelial cell surface. Biochem Bioph Res Co 111:723-731
97. Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, Fields PA, Burton M, Bellinger DA, Read MS, Brinkhous KM, Podsakoff GM, Nichols TC, Kurtzman GJ, High KA. 1999. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-asssocated viral vector. Nat Med 5:56-63.
98. Herzog RW, Mount JD, Arruda VR, High KA, Lothrop CD Jr. 2001. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther 4:192-200.
99. Herzog RW, Fields PA, Arruda VR, Brewbaker J, Armstrong E, McClintock D, Bellinger DA, Couto LB, Nichols TC, High KA. 2002. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther 13:1281-1291.
100. High KA. 2005. Gene transfer for hemophilia: Can therapeutic efficacy in large animals be safely translated to patients? J Thromb Hæmost 3:1682-1691.
101. Hill-Eubanks D, Lollar P. 1990. von Willebrand factor is a cofactor for thrombin-catalyzed cleavage of the factor VIII light chain. J Biol Chem 265:17854-17858.
102. Hough C, Kamisue S, Cameron C, Notley C, Tinlin S, Giles A, Lillicrap D. 2002. Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: Similarities with the intron 22 inversion mutation in human hemophilia. Thromb Hæmost 87:659-665.
103. Howard T, Machiah DK, Tran TT, Viel KR, Channell C, Soria JM, Ameri A, Iyer RV, Brown C, Doering C, Almasy L, Watts R, Davis J, Abshire TC. 2004. African-Americans express multiple haplotypic forms of the wildtype factor VIII (FVIII) protein: A possible role for pharmacogenetics in FVIII inhibitor development? Blood 104 (suppl 1):113a.
104. Hoyer LW. 1994. Hemophilia A. N Engl J Med 330:38-47.
105. Ishiwata A, Mimuro J, Kashiwakura Y, Niimura M, Takano K, Ohmori T, Madoiwa S, Mizukami H, Okada T, Naka H, Yoshioka A, Ozawa K, Sakata Y. 2006. Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene. Thromb Res 118:627-635.
106. Ivics Z, Hackett PB, Plasterk RH, Izsvak Z. 1997. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 91:501-510.
107. Jankowitz RG, Ragni MV, Chapman HL, Merricks EP, Kloos MT, Dillow AM, Franck HWG, Nichols TC. 2008. Recombinant interleukin-11 in women with refractory menorrhagia and von Willebrand disease. Blood 112:Abstract 1210.
108. Jiang H, Lillicrap D, Patarroyo-White S, Liu T, Qian X, Scallan CD, Powell S, Keller T, McMurray M, Labelle A, Nagy D, Vargas JA, Zhou S, Couto LB, Pierce GF. 2006a. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 108:107-115.
109. Jiang H, Pierce GF, Ozelo MC, de Paula EV, Vargas JA, Smith P, Sommer J, Luk A, Manno CS, High KA, Arruda VR. 2006b. Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther 14:452-455.
110. Jones TC. 1980. The value of animal models. Am J Path 101:S3-S9.
111. Kaae JA, Callan MB, Brooks M. 2007. Hereditary factor VII deficiency in the Alaskan Klee Kai dog. J Vet Intern Med 21:976-981.
112. Kafri T, Blomer U, Peterson DA, Gage FH, Verma IM. 1997. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 17:314-317.
113. Kay MA, Rothenberg S, Landen CN, Bellinger DA, Leland F, Toman C, Finegold M, Thompson AR, Read MS, Brinkhous KM, Woo SLC. 1993. In vivo gene therapy of hemophilia B: Sustained partial correction in factor IX-deficient dogs. Science 262:117-119.
114. Kay MA, Landen CN, Rothenberg SR, Taylor LA, Leland F, Wiehle S, Fang B, Bellinger D, Finegold M, Thompson AR, Read MS, Brinkhous KM, Woo SLC. 1994. In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci U S A 91:2353-2357.
115. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, Tai SJ, Herzog RW, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake AW, High KA. 2000. Evidence for gene transfer and expression of factor IX in hæmophilia B patients treated with an AAV vector [see comments]. Nat Genet 24:257-261.
116. Kaye J, Loewy J, Blume J, Clendaniel A, Egan A, Garnick MB, Mitchell J, Knowles C, Ault K. 1994. Recombinant human interleukin eleven (Neumega rhIL-ss growth factor) increases plasma von Willebrand factor and fibrinogen concentrations in normal human subjects. Blood 84:1088a.
117. Kiechl S, Willeit J. 2003. Cardiovascular protection in hæmophilia. Lancet 362:2026.
118. Kingdon HS, Johnson RC, Brauker JH, Johnson RC, Carr-Brendel VE, Lozier JN, High KA. 1993. An immunoisolation device which facilitates cell-based prophylactic therapy for hemophilia. Blood 82:1772.
119. Klitgaard T, Nielsen TG. 2008. Overview of the human pharmacokinetics of recombinant activated factor VII. Br J Clin Pharmacol 65:3-11.
120. Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT. 1996. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci U S A 93:5731-5736.
121. Koedam JA, Meijers JCM, Sixma JJ, Bouma BN. 1988. Inactivation of human factor VIII by activated protein C: Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 82:1236-1243.
122. Koutts J, Walsh PN, Plow EF, Fenton JW, Bouma BN, Zimmerman TS. 1978. Active release of human platelet factor VIII-related antigen by adenosine diphosphate, collagen, and thrombin. J Clin Invest 62:1255-1263.
123. Kren B, Bandyopadhyay P, Presnell S, Bellinger D, Nichols T, Steer C. 1998. Site-directed correction of the hemophilia B point mutation in genomic DNA of isolated dog hepatocytes by a chimeric RNA/DNA oligonucleotide. Am Soc Gene Ther Abstracts:181a.
124. Lakich D, Kazazian H Jr, Antonarakis SE, Gitschier J. 1993. Inversions disrupting the factor VIII gene are a common cause of severe hæmophilia A. Nat Genet 5:236-241.
125. Lamont PA, Ragni MV. 2005. Lack of desmopressin (DDAVP) response in men with hemophilia A following liver transplantation. J Thromb Hæmost 3:2259-2263.
126. Langdell RD, Wagner RH, Brinkhous KM. 1953. Effect of antihemophilic factor on one-stage clotting tests. J Lab Clin Med 41:637-647.
127. Lieber A, He C-Y, Kirillova I, Kay MA. 1996a. Recombinant adenoviruses with large deletions generated by CRE-mediated excision exhibit different biological properties compared with first generation vectors in vitro and in vivo. J Virol 70:8944-8960.
128. Lieber A, He CY, Kay MA. 1996b. Adenoviral preterminal protein stabilizes mini-adenoviral genomes in vitro and in vivo. Nat Biotechnol 15:1383-1387.
129. Liles D, Landen CN, Monroe DM, Lindley CM, Read MS, Roberts HR, Brinkhous KM. 1997. Extravascular administration of factor IX: Potential for replacement therapy of canine and human hemophilia B. Thromb Hæmost 77:944-948.
130. Lillicrap D, VandenDriessche T, High K. 2006. Cellular and genetic therapies for hæmophilia. Hæmophilia 12 Suppl 3:36-41.
131. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. 2000. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 105:71-77.
132. Lin Y, Chang L, Solovey A, Healey JF, Lollar P, Hebbel RP. 2002. Use of blood outgrowth endothelial cells for gene therapy for hemophilia A. Blood 99:457-462.
133. Liu YL, Zhu H, Schlachterman A, Chang H, Camire RM, High KA. 2004. A novel deletion in the FVIII B-domain that reduces transgene size while preserving FVIII activity. Blood 104:Abstract 3182.
134. Liu L, Mah C, Fletcher BS. 2006. Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon. Mol Ther 13:1006-1015.
135. Lozier JN. 2004. Gene therapy of the hemophilias. Semin Hematol 41:287-296.
136. Lozier JN, Brinkhous KM. 1994. Gene therapy and the hemophilias. JAMA 271:47-51.
137. Lozier JN, Palmer TD, Thompson AR, Miller AD, Brinkhous KM, High KA. 1991. Production of recombinant canine factor IX by hollow fiber tissue culture. Thromb Hæmost 65:1158.
138. Lozier JN, Thompson AR, Hu PC, Read M, Brinkhous KM, High KA, Curiel DT. 1994. Efficient transfection of primary cells in a canine hemophilia B model using adenovirus-polylysine-DNA complexes. Hum Gene Ther 5:313-322.
139. Lozier JN, Dutra A, Pak E, Zhou N, Zheng Z, Nichols TC, Bellinger DA, Read M, Morgan RA. 2002. The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion. Proc Natl Acad Sci U S A 99:12991-12996.
140. Lu H, Chen L, Wang J, Huack B, Sarkar R, Zhou S, Xu R, Ding Q, Wang X, Wang H, Xiao W. 2008. Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette. Hum Gene Ther 19:648-654.
141. Macfarlane RG. 1965. Hæmorrhagic diseases in surgery: The Hæmostatic defect in Hæmophilia and its temporary correction. Proc R Soc Med 58:251-255.
142. Mackman N, Tilley RE, Key NS. 2007. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscl Throm Vas 27:1687-1693.
143. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros D, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, Evatt BL. 2007. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 357:535-544.
144. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR, Tai SJ, Ragni MV, Thompson A, Ozelo M, Couto LB, Leonard DG, Johnson FA, McClelland A, Scallan C, Skarsgard E, Flake AW, Kay MA, High KA, Glader B. 2003. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101:2963-2972.
145. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC,
146. Mannucci PM, Tuddenham EG. 2001. The hemophilias: From royal genes to gene therapy. N Engl J Med 344:1773-1779.
147. Mannucci P, Moia M, Rebulla P, Altieri D, Monteagudo J, Castillo R. 1987. Correction of the bleeding time in treated patients with severe von Willebrand disease is not solely dependent on the normal multimeric structure of plasma von Willebrand factor. Am J Hematol 25:55-65.
148. Mannucci PM, Abshire T, DiMichele D, Santagostino E, Blanchette V. 2006. Inhibitor development, immune tolerance and prophylaxis in hæmophilia A: The need for an evidence-based approach. Hæmophilia 12:429-434.
149. Marchioro TL, Hougie C, Ragde H, Epstein RB, Thomas ED. 1969. Hemophilia: Role of organ homografts. Science 163:188-190.
150. Margaritis P, Arruda VR, Aljamali M, Camire RM, Schlachterman A, High KA. 2004. Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated factor VII. J Clin Invest 113:1025-1031.
151. Margaritis P, Roy E, Aljamali MN, Downey HD, Giger U, Zhou S, Merricks E, Dillow A, Ezban M, Nichols TC, High KA. 2008. Successful treatment of canine hemophilia by continuous expression of canine FVIIa. Blood: prepublished online Dec 23, 2008; doi: 10.1182/blood-2008-07-168377.
152. Mariani G, Testa MG, Di Paolantonio T, Molskov Bech R, Hedner U. 1999. Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sang 77:131-136.
153. Matsui H, Shibata M, Brown B, Labelle A, Hegadorn C, Andrews C, Hebbel RP, Galipeau J, Hough C, Lillicrap D. 2007. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo FVIII expression from lentivirally-engineered endothelial progenitors. Stem Cell 25:2660-2669.
154. Matsushita T, Elliger S, Elliger C, Podsakoff G, Villarreal L, Kurtzman GJ, Iwaki Y, Colosi P. 1998. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther 5:938-945.
155. Mauser AE, Whitlark J, Whitney KM, Lothrop CD Jr. 1996. A deletion mutation causes hemophilia B in Lhasa Apso dogs. Blood 88:3451-3455.
156. McCarthy K, Stewart P, Sigman J, Read M, Keith JC, Brinkhous KM, Nichols TC, Schaub RG. 2002. Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys. J Thromb Hæmost 87:824-830.
157. McCormack WM Jr, Seiler MP, Bertin TK, Ubhayakar K, Palmer DJ, Ng P, Nichols TC, Lee B. 2006. Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model. J Thromb Hæmost 4:1218-1225.
158. Miao CH, Chou SH, Nichols TC, Thompson AR. 1999. Chimeric RNA/DNA hybrid dumbbells capped with compact trinucleotide loops more consistently corrects the factor IX point mutation in canine hemophilic fibroblasts. Blood 94 (Suppl 1):373a.
159. Miao CH, Chou SH, Nichols TC, Thompson AR. 2000. Targeted gene repair in canine hemophilia fibroblasts by chimeric RNA/DNA hybrid dumbbells capped with compact trinucleotide loops. Mol Ther 1(abstr suppl):S291.
160. Miao CH, Ye P, Thompson AR, Rawlings DJ, Ochs HD. 2006. Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice. Blood 108:19-27.
161. Miao HZ, Sirachainan N, Palmer L, Kucab P, Cunningham MA, Kaufman RJ, Pipe SW. 2004. Bioengineering of coagulation factor VIII for improved secretion. Blood 103:3412-3419.
162. Milbauer LC, Enenstein J, Roney M, Solovey A, Bodempudi V, Nichols TC, Hebbel RP. 2008. BOEC migration and trapping in vivo: A window into gene therapy. Transl Res (accepted).
163. Mingozzi F, High KA. 2007. Immune responses to AAV in clinical trials. Curr Gene Ther 7:316-324.
164. Monahan PE. 2007. Neonatal immune tolerance for hemophilia: Can we 'tolerate' new paradigms for gene therapy trials? J Thromb Hæmost 5:1801-1804.
165. Monahan PE, White GC 2nd. 2002. Hemophilia gene therapy: Update. Curr Opin Hematol 9:430-436.
166. Monahan PE, Samulski RJ, Tazelaar J, Xiao X, Nichols TC, Bellinger DA, Read MS, Walsh CE. 1998. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther 5:40-49.
167. Monroe DM, Hoffman M, Roberts HR. 2002. Platelets and thrombin generation. Arterioscl Throm Vas 22:1381-1389.
168. Monroe DM, Hoffman M, Roberts HR. 2007. Fathers of modern coagulation. Thromb Hæmost 98:3-5.
169. Mount JD, Herzog RW, Tillson DM, Goodman SA, Robinson N, McCleland ML, Bellinger D, Nichols TC, Arruda VR, Lothrop CD Jr, High KA. 2002. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 99:2670-2676.
170. Mustard JF, Secord D, Hoeksema TD, Downie HG, Rowsell HC. 1962. Canine factor-VII deficiency. Br J Haematol 8:43-47.
171. Nakai H, Yant SR, Storm TA, Fuess S, Meuse L, Kay MA. 2001. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol 75:6969-6976.
172. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267.
173. Nathwani AC, Davidoff A, Hanawa H, Zhou JF, Vanin EF, Nienhuis AW. 2001. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. Blood 97:1258-1265.
174. Nathwani AC, Davidoff AM, Tuddenham EG. 2004. Prospects for gene therapy of hæmophilia. Hæmophilia 10:309-318.
175. Nathwani AC, Gray JT, McIntosh J, Ng CY, Zhou J, Spence Y, Cochrane M, Gray E, Tuddenham EG, Davidoff AM. 2007. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood 109:1414-1421.
176. Naylor J, Brinke A, Hassock S, Green PM, Giannelli F. 1993. Characteristic mRNA abnormality found in half the patients with severe Hæmophilia A is due to large DNA inversions. Hum Mol Genet 2:1773-1778.
177. Neyman M, Gewirtz J, Poncz M. 2008. Analysis of the spatial and temporal characteristics of platelet-delivered factor VIII-based clots. Blood 112:1101-1108.
178. Nichols TC, Bellinger DA, Reddick RL, Smith SV, Koch GG, Davis K, Sigman J, Brinkhous KM, Griggs TR, Read MS. 1993. The roles of von Willebrand factor and factor VIII in arterial thrombosis: Studies in canine von Willebrand disease and hemophilia A. Blood 81:2644-2651.
179. Nichols TC, Samama CM, Bellinger DA, Roussi J, Reddick RL, Bonneau M, Read MS, Bailliart O, Koch GG, Vaiman M, Sigman JL, Pignaud GA, Brinkhous KM, Griggs TR, Drouet L. 1995. Function of von Willebrand factor after crossed bone marrow transplantation between normal and von Willebrand disease pigs: Effect on arterial thrombosis in chimeras. Proc Natl Acad Sci U S A 92:2455-2459.
180. Nichols TC, Pipe SW, Kaufman RJ, McClintock DWD, Zollner R, Booth J, Schaub RG, Read MS. 1999. Inactivation-resistant human coagulation factor VIIIa (IR8) corrects canine hemophilia A coagulopathy. Thromb Hæmost 82 (abstr suppl XVII Congress of the ISTH):488.
181. Nichols TC, Merricks E, Muchitsch EM, Baumgartner B, Turecek PL, Ahmad RU, Gritsch H, Schwarz HP. 2007. Pharmacokinetics (PK) of rVWF in dogs and mice with VWD. XXI ISTH Abstracts:P-W-197.
182. Nichols WL, Hultin MB, James AH, Manco-Johnson MJ, Montgomery RR, Ortel TL, Rick ME, Sadler JE, Weinstein M, Yawn BP. 2008. von Willebrand disease (VWD): Evidence-based diagnosis and management guidelines. National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Hæmophilia 14:171-232.
183. Niemeyer GP, Herzog RW, Mount J, Arruda VR, Tillson DM, Hathcock J, van Ginkel FW, High KA, Lothrop CD Jr. 2008. Long term correction of inhibitor prone hemophilia B dogs treated with liver-directed AAV2 mediated factor IX gene therapy. Blood: prepublished online Oct 28, 2008; doi: 10.1182/blood-2008-10- 181479.
184. Ohlfest JR, Frandsen JL, Fritz S, Lobitz PD, Perkinson SG, Clark KJ, Nelsestuen G, Key NS, McIvor RS, Hackett PB, Largaespada DA. 2005. Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system. Blood 105:2691-2698.
185. Oldenburg J, Schwaab R. 2001. Molecular biology of blood coagulation. Semin Thromb Hemost 27:313-324.
186. Olsen EHN, McCain AS, Merricks EP, Fischer TH, Dillon IM, Raymer RA, Bellinger DA, Fahs SA, Montgomery RR, Keith JC Jr, Schaub RG, Nichols TC. 2003. Comparative response of plasma VWF in dogs to up-regulation of VWF mRNA by interleukin-11 versus Weibel-Palade body release by desmopressin (DDAVP). Blood 102:436-441.
187. Othman M, Labelle A, Mazzetti I, Elbatarny HS, Lillicrap D. 2007. Adenovirus-induced thrombocytopenia: The role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood 109:2832-2839.
188. Owen CA Jr. 2001. A History of Blood Coagulation. Nichols WL, Bowie EJW, eds. Rochester MN: Mayo Foundation for Medical Education and Research.
189. Park F, Ohashi K, Kay MA. 2000. Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. Blood 96:1173-1176.
190. Parker RI, McKeown LP, Gallin JI, Gralnick HR. 1992. Absence of the largest platelet-von Willebrand multimers in a patient with lactoferrin deficiency and a bleeding tendency. Thromb Hæmost 67:320-324.
191. Pasi KJ. 2001. Gene therapy for Hæmophilia. Br J Hæmatol 115:744-757.
192. Patek AJ, Taylor FH. 1937. Hemophilia. II. Some properties of a substance obtained from normal human plasma effective in accelerating the coagulation of hemophilic blood. J Clin Invest 16:113-24.
193. Pemberton S. 2004. Canine Technologies, Model Patients: The Historical Production of Hemophiliac Dogs in American Biomedicine. New York: Routledge. p 191-213.
194. Pipe SW. 2004. Coagulation factors with improved properties for hemophilia gene therapy. Semin Thromb Hemost 30:227-237.
195. Pipe SW, Kaufman RJ. 1997. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc Natl Acad Sci U S A 94:11851-11856.
196. Pipe SW, Nichols TC, McClintock DWD, Zollner R, Thomas J, Schaub R, Read MS, Saenko EL, Kaufman RJ. 1999. The conformation of the factor VIII light chain can modulate von Willebrand factor binding affinity without affecting cofactor activity in vitro and in vivo. Blood 94 (Suppl 1):453a.
197. Ponder KP. 2006. Gene therapy for hemophilia. Curr Opin Hematol 13:301-307.
198. Powell JS, Ragni MV, White GC 2nd, Lusher JM, Hillman-Wiseman C, Moon TE, Cole V, Ramanathan-Girish S, Roehl H, Sajjadi N, Jolly DJ, Hurst D. 2003. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood 102:2038-2045.
199. Ragni MV, Jankowitz RC, Chapman HL, Merricks EP, Kloos MT, Dillow AM, Nichols TC. 2008. A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease. Hæmophilia 14:968-977.
200. Rawle FE, Lillicrap D. 2004. Preclinical animal models for hemophilia gene therapy: Predictive value and limitations. Semin Thromb Hemost 30:205-213.
201. Read MS, Shermer RW, Brinkhous KM. 1978. Venom coagglutinin: An activator of platelet aggregation dependent on von Willebrand Factor. Proc Natl Acad Sci U S A 75:4514-4518.
202. Recombinant DNA Advisory Committee Meeting. 2002. Recombinant DNA Advisory Committee Meeting March 7, 2002. Hum Gene Ther 13:989-1000.
203. Rieger M, Schwarz HP, Turecek PL, Dorner F, van Mourik JA, Mannhalter C. 1998. Identification of mutations in the canine von Willebrand factor gene associated with type III von Willebrand disease. Thromb Hæmost 80:332-337.
204. Roosendaal G, Lafeber F. 2007. Prophylactic treatment for prevention of joint disease in hemophilia: Cost versus benefit. N Engl J Med 357:603-605.
205. Roth DA, Tawa NE Jr, O'Brien JM, Treco DA, Selden RF. 2001. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 344:1735-1742.
206. Ruggeri ZM, Ware J. 1993. von Willebrand factor. FASEB J 7:308-316.
207. Russell KE, Read MS, Bellinger DA, Leitermann K, Rup BJ, McCarthy KP, Keith JC, Schaub RG, Khor SP, Nichols TC. 2001. Intratracheal administration of recombinant human factor IX (BeneFixTM) achieves therapeutic levels in hemophilia B dogs. Thromb Hæmost 85:445-449.
208. Russell KE, Olsen EHN, Raymer RA, Merricks EP, Bellinger DA, Read MS, Rup BJ, Keith JC Jr, McCarthy KP, Schaub RG, Nichols TC. 2003. Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune tolerant hemophilia B dogs. Blood 102:4393-4398.
209. Sabatino D, Lange AM, Sarkar R, Dillow AM, Nichols TC, Arruda VR, Kazazian HH. 2007. Successful long term expression of F.VIII after gene delivery of novel adeno-associated viral vector serotypes in hemophilia A dogs. XXI ISTH Abstracts:P-w-231.
210. Sadler JE. 2005. von Willebrand factor: Two sides of a coin. J Thromb Hæmost 3:1702-1709.
211. Sadler JE, Rodeghiero F. 2005. Provisional criteria for the diagnosis of VWD type 1. J Thromb Hæmost 3:775-777.
212. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, Federici AB. 2006. Update on the pathophysiology and classification of von Willebrand disease: A report of the Subcommittee on von Willebrand Factor. J Thromb Hæmost 4:2103-2114.
213. Samulski RJ, Zhu X, Xiao X, Brook JD, Bouseman DE, Epstein N, Hunter LA. 1991. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 10:3941-3950.
214. Sarkar R, Tetreault R, Gao G, Wang L, Bell P, Chandler R, Wilson JM, Kazazian HH Jr. 2004. Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood 103:1253-1260.
215. Sarkar R, Mucci M, Addya S, Tetreault R, Bellinger DA, Nichols TC, Kazazian HH. 2006. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia A dogs and mice. Hum Gene Ther 17:427-439.
216. Scallan CD, Liu T, Parker AE, Patarroyo-White SL, Chen H, Jiang H, Vargas J, Nagy D, Powell SK, Wright JF, Sarkar R, Kazazian HH, McClelland A, Couto LB. 2003. Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII. Blood 102:3919-3926.
217. Schiedner G, Morral N, Parks RJ, Wu Y, Koopmans SC, Langston C, Graham FL, Beaudet AL, Kochanek S. 1998. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 18:180-184.
218. Schneppenheim R, Thomas KB, Sutor AH. 1995. Von Willebrand disease in childhood. [Review]. Semin Thromb Hemost 21:261-275.
219. Schuettrumpf J, Herzog RW, Schlachterman A, Kaufhold A, Stafford DW, Arruda VR. 2005. Factor IX variants improve gene therapy efficacy for hemophilia B. Blood 105:2316-2323.
220. Schultz BR, Chamberlain JS. 2008. Recombinant adeno-associated virus transduction and integration. Mol Ther 16:1189-1199.
221. Shapiro AD, Di Paola J, Cohen A, Pasi KJ, Heisel MA, Blanchette VS, Abshire TC, Hoots WK, Lusher JM, Negrier C, Rothschild C, Roth DA. 2005. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood 105:518-525.
222. Sheldon-Inloes BB, Titani K, Sadler JE. 1986. cDNA sequences for human von Willebrand factor reveal five types of repeated domains and five possible protein sequence polymorphisms. Biochemistry 25:3164-3171.
223. Shi Q, Wilcox DA, Fahs SA, Kroner PA, Montgomery RR. 2003. Expression of human factor VIII under control of the platelet-specific alphaIIb promoter in megakaryocytic cell line as well as storage together with VWF. Mol Genet Metab 79:25-33.
224. Shi Q, Wilcox DA, Fahs SA, Weiler H, Wells CW, Cooley BC, Desai D, Morateck PA, Gorski J, Montgomery RR. 2006. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. J Clin Invest 116:1974-1982.
225. Sigman JL, Read MS, Stewart PF, Keith JC, Garzone P, McCarthy K, Schaub RG, Brinkhous KM. 1997. High molecular weight factor IX aggregate isolated from a highly purified plasma-derived concentrate does not correct hemostasis in the hemophilia B dog. Thromb Hæmost 77:220 (abstr suppl).
226. Sleeper MM, Bish LT, Sweeney HL. 2009. Gene therapy in large animal models of human cardiovascular genetic disease. ILAR J 50:199-205.
227. Smiley R, Titley P, Rock G. 1989. Studies on the prolonged bleeding time in von Willebrand's disease. Thromb Res 53:417-426.
228. Snyder RO, Miao CH, Patijn GA, Spratt SK, Danos O, Nagy D, Gown AM, Winther B, Meuse L, Cohen LK, Thompson AR, Kay MA. 1997. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 16:270-276.
229. Snyder RO, Miao C, Meuse L, Donahue BA, Lin H-F, Stafford DW, Patel S, Thompson A, Nichols T, Bellinger D, Read M, Brinkhous KM, Kay MA. 1999. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med 5:64-70.
230. Sporn LA, Chavin SI, Marder V, Wagner D. 1985. Biosynthesis of von Willebrand protein by human megakaryocytes. J Clin Invest 76:1102-1106.
231. Sramek A, Kriek M, Rosendaal FR. 2003. Decreased mortality of ischæmic heart disease among carriers of hæmophilia. Lancet 362:351-354.
232. Stern DM, Knitter G, Kisiel W, Nawroth PP. 1987. In vivo evidence of intravascular binding sites for coagulation factor IX. Br J Hæmatol 66:227-232.
233. Sun J, Hakobyan N, Valentino LA, Feldman BL, Samulski RJ, Monahan PE. 2008. Intra-articular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX. Blood 112:4532-4541.
234. Tinlin S, Webster S, Giles AR. 1993. The development of homologous (canine/anti-canine) antibodies in dogs with hæmophilia A (factor VIII deficiency): A ten-year longitudinal study. Thromb Hæmost 69:21-24.
235. Tuddenham EGD. 2006. Factor VIII: Purer is not necessarily safer. Blood 107:4-5.
236. Van Cott KE, Monahan PE, Nichols TC, Velander WH. 2004. Hæmophilic factors produced by transgenic livestock: Abundance that can enable alternative therapies worldwide. Hæmophilia 10 Suppl 4:70-76.
237. van den Berg HM, De Groot PH, Fischer K. 2007. Phenotypic heterogeneity in severe hemophilia. J Thromb Hæmost 5 Suppl 1:151-156.
238. Viuff D, Ezban M, Lind V, Dillow A, Raymer R, Merricks E, Nichols T. 2007. Effect of rFVIIa and NN1731 (rFVIIa analogue) on thromboelastography (TEG) in whole blood obtained from hemophilia A dogs. XXI ISTH Abstracts:P-W-113.
239. Wagner RH, Langdell RD, Richardson BA, Farrell RA, Brinkhous KM. 1957. Antihemophilic factor (AHF): Plasma levels after administration of AHF preparations to hemophilic dogs. Proc Soc Exp Biol Med 96:152-155.
240. Wagner RH, Roberts HR, Webster WP, Shanbrom E, Brinkhous KM. 1968. Glycine-precipitated antihemophilic factor concentrates and their clinical use. Thromb Diath Hæmorrh Suppl 35:41-48.
241. Wang L, Nichols TC, Read MS, Bellinger DA, Verma IM. 2000. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther 1:154-158.
242. Wang L, Calcedo R, Nichols TC, Bellinger DA, Dillow A, Verma IM, Wilson JM. 2005. Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood 105:3079-3086.
243. Wang Z, Chamberlain JS, Tapscott SJ, Storb R. 2009. Gene therapy in large animal models of muscular dystrophy. ILAR J 50:187-198.
244. Webster WP, Roberts HR, Thelin GM, Wagner RH, Brinkhous KM. 1965. Clinical use of a new glycine-precipitated antihemophilic fraction. Amer J Med Sci 250:643-651.
245. Webster WP, Penick GD, Peacock EE, Brinkhous KM. 1967. Allotransplantation of spleen in hemophilia. NC Med J 28:505-507.
246. Webster WP, Zukoski CF, Hutchin P, Reddick RL, Mandel SR, Penick GD. 1971. Plasma factor VIII synthesis and control as revealed by canine organ transplantation. Am J Physiol 220:1147-1154.
247. Webster WP, Mandel SR, Reddick RL, Wagner JL, Penick GD. 1974. Orthotopic liver transplantation in canine hemophilia B. Am J Physiol 226:496-500.
248. White GC. 2002. Gutted Adenoviral Vector Delivering Factor VIII: Clinical Results. National Hemophilia Foundation Fifth Workshop on Gene Therapies for Hemophilia. Philadelphia.
249. White GC, Beebe A, Nielson B. 1997. Recombinant Factor IX. Thromb Hæmost 78:261-265.
250. Wilcox DA, Shi Q, Nurden P, Haberichter SL, Rosenberg JB, Johnson BD, Nurden AT, White GC 2nd, Montgomery RR. 2003. Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII. J Thromb Hæmost 1:2477-2489.
251. Wolberg AS, Stafford DW, Erie DA. 1997. Human factor IX binds to specific sites on the collagenous domain of collagen IV. J Biol Chem 272:16717-16720.
252. Wu QY, Drouet L, Carrier JL, Rothschild C, Berard M, Rouault C, Caen J, Meyer D. 1987. Differential distribution of von Willebrand factor in endothelial cells: Comparison between normal pigs and pigs with von Willebrand disease. Arteriosclerosis 7:47-54.
253. Wu SM, Stafford DW, Frazier LD, Fu YY, High KA, Chu K, Sanchez-Vega B, Solera J. 1997. Genomic sequence and transcription start site for the human gamma-glutamyl carboxylase. Blood 89:4058-4062.
254. Wu Z, Sun J, Zhang T, Yin C, Yin F, Van Dyke T, Samulski RJ, Monahan PE. 2008. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther 16:280-289.
255. Xiao X, Li J, Samulski RJ. 1996. Efficient long-term gene transfer into muscle tissue of immunocompentent mice by adeno-associated virus vector. J Virol 70:8098-8108.
256. Xiao X, Li J, Samulski RJ. 1998. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 72:2224-2232.
257. Xu K, Ma H, McCown TJ, Verma IM, Kafri T. 2001. Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol Ther 3:97-104.
258. Xu L, Gao C, Sands MS, Cai SR, Nichols TC, Bellinger DA, Raymer RA, McCorquodale S, Ponder KP. 2003. Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B. Blood 101:3924-3932.
259. Xu L, Nichols TC, Sarkar R, McCorquodale S, Bellinger DA, Ponder KP. 2005. Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy. Proc Natl Acad Sci U S A 102:6080-6085.
260. Xu L, Mei M, Haskins ME, Nichols TC, O'Donnell P, Cullen K, Dillow A, Bellinger D, Ponder KP. 2007. Immune response after neonatal transfer of a human factor IX-expressing retroviral vector in dogs, cats, and mice. Thromb Res 120:269-280.
261. Yan JB, Wang S, Huang WY, Xiao YP, Ren ZR, Huang SZ, Zeng YT. 2006. Transgenic mice can express mutant human coagulation factor IX with higher level of clotting activity. Biochem Genet 44:349-360.
262. Yarovoi HV, Kufrin D, Eslin DE, Thornton MA, Haberichter SL, Shi Q, Zhu H, Camire R, Fakharzadeh SS, Kowalska MA, Wilcox DA, Sachais BS, Montgomery RR, Poncz M. 2003. Factor VIII ectopically expressed in platelets: Efficacy in hemophilia A treatment. Blood 102:4006-4013.
263. Ye P, Thompson AR, Sarkar R, Shen Z, Lillicrap DP, Kaufman RJ, Ochs HD, Rawlings DJ, Miao CH. 2004. Naked DNA transfer of factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice. Mol Ther 10:117-126.
264. Zauber NP, Levin J. 1977. Factor IX levels in patients with hemophilia B (Christmas disease) following transfusion with concentrates of factor IX or fresh frozen plasma (FFP). Medicine (Baltimore) 56:213-224.
265. Zhang Z, Eriksson M, Falk G, Graff C, Presnell SC, Read MS, Nichols TC, Blomback M, Anvret M. 1998. Failure to achieve gene conversion with chimeric circular oligonucleotides: Potentially misleading PCR artifacts observed. Antisense Nucleic A 8:531-536.